ALEXANDRIA, Va., June 19 -- United States Patent no. 12,331,113, issued on June 17, was assigned to ARIALYS THERAPEUTICS INC. (La Jolla, Calif.).
"Anti-human NR1 antibody derivative" was invented by Satoshi Kubo (Tokyo), Atsuo Kanno (Tokyo), Daisuke Yamajuku (Tokyo), Takuya Kito (Tokyo), Masashi Maeda (Tokyo) and Takuma Mihara (Tokyo).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention addresses the problem of providing a novel therapeutic agent for treating patients with anti NMDAR encephalitis. Patients with an anti NMDAR encephalitis have a pathogenic anti-human NR1 antibody that induces internalization of NMDAR on cell surface. As a result, NMDAR function is weakened in the patients' brai...